Mon 25 July 2022:
As the World Health Organization (WHO) declared the monkeypox outbreak in more than 50 countries a “emergency of international concern,” the EU is stepping up public health plans to combat the virus.
The European Commission on Monday approved the vaccine for use against the monkeypox virus in the European Union, and by extension Norway, Iceland and Liechtenstein.
A commission spokesperson confirmed the decision after the pharmaceutical company, Bavarian Nordic, announced the vaccine’s approval.
The move follows a recommendation from the European Medicines Agency (EMA) on Friday to expand the use of Imvanex to include monkeypox. In practice, the EU executive arm follows the EMA’s advice.
Prior to this, the vaccine was only approved at an EU-level to protect adults from smallpox.
The commission recently announced two contracts to purchase a total of 163,620 doses of Bavarian Nordic’s vaccine. The EU bought 110,000 in June, with 25,000 already distributed to six member states.
SOURCE: INDEPENDENT PRESS AND NEWS AGENCIES
___________________________________________________________________________________________________________________________________________
FOLLOW INDEPENDENT PRESS:
TWITTER (CLICK HERE)
https://twitter.com/IpIndependent
FACEBOOK (CLICK HERE)
https://web.facebook.com/ipindependent
Think your friends would be interested? Share this story!
